Articles
dorsaVi teams with insurer to promote OHS device
dorasVi (ASX:DVL) has entered a partnership with insurer Allianz to recommend the use of ViSafe - a device for measuring movement and muscle activity - for Australian labourers. [ + ]
Nanosonics taps German distributor for Trophon EPR
Miele Professional will distribute Nanosonics' (ASX:NAN) ultrasound probe disinfection system Trophon EPR in the German market. [ + ]
From cancer tissue to dying stars: Extreme Imaging 2014
The winners of the 2014 Extreme Imaging Competition were last night announced at the Powerhouse Museum. Now in its third year, the annual event is held by Canon Australia's local research and development arm, Canon Information Systems Research Australia (CiSRA). [ + ]
Patrys posts strong results from myeloma trial
Patrys (ASX:PAB) has said anticancer candidate PAT-SM6 was found to be safe and potentially effective during a phase I/IIa trial in multiple myeloma. [ + ]
Trialling a new enzyme inhibitor
The persistently high blood glucose levels associated with diabetes can, over time, cause damage to blood vessels that result in so-called diabetes-related complications. Preventing or reducing diabetes-related complications in the kidney is the focus of some of the work currently underway at the Baker IDI. [ + ]
Diagnostic device meets malaria field evaluation objective
Fio Corporation's Deki Reader - a mobile in vitro diagnostic device - has demonstrated consistent interpretation of rapid diagnostic tests (RDTs) for multiple malaria strains in a field evaluation. [ + ]
Cogstate tests to be used in Alzheimer's study
Cogstate (ASX:CGS) will supply cognition tests for a phase III trial involving using Eli Lilly's anti-amyloid drug Solanezumab to slow the onset of Alzheimer's disease. [ + ]
First evidence of cosmic inflation found
Researchers from the BICEP2 collaboration have announced the first direct evidence of cosmic inflation - the rapid expansion of the universe which immediately followed the Big Bang. Until now, the idea of this exponential expansion was just a theory. [ + ]
Ascend cancer drug shows potential in CBCL
More than 80% of patients with cutaneous B-cell lymphoma enrolled in a phase II trial of Ascend's in-licensed cancer drug ASN-002 demonstrated a complete or partial response to treatment. [ + ]
Millennium-old frozen moss comes back to life
Researchers from the British Antarctic Survey and the University of Reading have demonstrated for the first time that after over 1500 years frozen in Antarctic ice, moss can come back to life and continue to grow. [ + ]
Cochlear cleared to sell new device in US
The FDA has granted Cochlear (ASX:COH) approval to sell the Nucleus Hybrid L24 - a new cochlear implant system designed to address high-frequency hearing loss - in the US. [ + ]
Virax to buy Pathway Oncology
Virax Holdings (ASX:VHL) has arranged to buy Pathway Oncology, a company with an exclusive licence to a cancer drug candidate due to enter phase II trials in breast cancer and multiple myeloma. [ + ]
Imugene kicks off IND process for HER-Vaxx
Imugene (ASX:IMU) has appointed Ground Zero Pharmaceuticals to help the company prepare its Investigational New Drug application with the US FDA for cancer vaccine HER-Vaxx. [ + ]
The best laid plans of mice in men
Scientists from the UK and Australia have created a mouse strain that expresses a fluorescing biosensor in every cell of its body, allowing diseased cells and drugs to be tracked and evaluated in real time. [ + ]
Rapid DNA profiling for FBI
IntegenX, a developer of rapid human DNA identification technology, has met the US FBI guidelines to upload directly to the National DNA Index System (NDIS) known arrestee and convicted offender DNA profiles, as well as casework known samples. The profiles will be generated with the RapidHIT System using Life Technologies GlobalFiler Express kits from Thermo Fisher Scientific. [ + ]